Singapore, April 16 -- Japan-based Nxera Pharma, formerly known as Sosei Group or Sosei Heptares, has entered into an exclusive supply and distribution agreement with Handok Inc. to commercialise PIVLAZ (clazosentan sodium) 150 mg in South Korea.

Under the terms of the agreement, Nxera Pharma Korea will provide drug product to Handok at an agreed price and Handok is exclusively responsible for the promotion, marketing, sales and distribution of PIVLAZ in South Korea. Nxera will receive a one-off upfront payment from Handok upon signing of the agreement and is eligible for further commercial milestone payments plus sales coming from product supply.

PIVLAZ is approved in South Korea for the prevention of cerebral vasospasm, vasospasm-rela...